Constipation Treatment Drug

Constipation Treatment Drug Market Outlook

The global constipation treatment drug market is poised to reach an estimated USD 5.8 billion by 2035, growing at a CAGR of 5.3% from 2025 to 2035. This growth can be attributed to the increasing prevalence of constipation-related disorders, particularly among aging populations, who are more susceptible to gastrointestinal issues. Additionally, the rise in awareness regarding chronic constipation management and the introduction of innovative therapeutic agents have energized market growth. The growing trend of self-medication and over-the-counter (OTC) laxatives is increasingly influencing the market landscape, as consumers seek convenient solutions to manage their healthcare needs independently. Furthermore, the expansion of online pharmacies has made access to these medications easier, driving the demand for constipation treatment drugs across various demographics.

Growth Factor of the Market

The constipation treatment drug market is benefitting from several growth factors that are driving its expansion. One of the primary factors is the rising incidence of constipation globally, which is often exacerbated by lifestyle changes, dietary habits, and sedentary behavior. Additionally, the increase in the elderly population, which is more prone to chronic health conditions and medication-related constipation, has led to a higher demand for effective treatment options. Furthermore, advancements in pharmacological research and development have resulted in a new class of drugs, providing patients with more targeted and efficient therapies. The growing trend of preventive healthcare is also encouraging patients to seek treatment before complications arise, thus fueling market demand. Lastly, increased focus on consumer education about gastrointestinal health and the importance of timely treatment of constipation are further amplifying growth opportunities within this market.

Key Highlights of the Market

• Expected market growth from USD 5.8 billion by 2035, driven by increased prevalence of constipation.
• Expansion of online pharmacies enhancing consumer access to constipation treatment drugs.
• Innovative drug development leading to more effective treatment options for chronic constipation.
• Growing awareness among consumers regarding the importance of gastrointestinal health.
• Rising preference for over-the-counter medications contributing to market dynamics.

By Product Type

Laxatives:

Laxatives represent a significant segment within the constipation treatment drug market, encompassing various formulations designed to stimulate bowel movements or soften stool. These medications are commonly used for short-term relief of constipation and are categorized into three types: bulk-forming, stimulant, and osmotic laxatives. Bulk-forming laxatives, such as psyllium, absorb water in the intestines to facilitate bowel movement, while stimulant laxatives, like bisacodyl, directly stimulate the intestinal muscles. Osmotic laxatives, which include polyethylene glycol, draw water into the bowel, making stool passage easier. The popularity of laxatives is continuously growing due to their efficacy and wide availability, making them a common first-line treatment choice for patients experiencing constipation.

Fiber Supplements:

Fiber supplements play a crucial role in mitigating constipation symptoms by promoting regular bowel movements through increased stool bulk. They are derived from natural sources such as psyllium husk and other plant-based fibers. Fiber supplements are particularly beneficial for individuals who do not obtain sufficient dietary fiber, thus suffering from occasional constipation. They work by absorbing water in the intestines, which helps to soften the stool and promote movement through the digestive tract. The rising trend of health-conscious consumers seeking natural remedies has significantly boosted the fiber supplement segment, driving sales in both the retail and online markets.

Stimulants:

Stimulants are another vital category within the constipation treatment drug market. These medications work by enhancing the contractions of the intestinal muscles, thereby promoting bowel movement. Common stimulant drugs include bisacodyl and senna. Due to their rapid action and effectiveness, stimulant laxatives are often recommended for occasional constipation relief. However, their use is typically not advised for long-term management due to potential dependency or diminished bowel function. The increasing prevalence of opioid-induced constipation, particularly among patients receiving pain management therapy, has further fueled the demand for stimulant laxatives, highlighting their significance in the overall market.

Osmotic Agents:

Osmotic agents are designed to bring water into the bowel, softening the stool and encouraging bowel movements. These agents include polyethylene glycol and lactulose, which are commonly prescribed for patients with chronic constipation. Osmotic agents are highly regarded for their ability to provide effective and gentle relief without causing significant cramping or discomfort. The demand for these agents has surged as healthcare professionals increasingly recognize their safety and efficacy, particularly for long-term use in patients with chronic conditions. The growing acceptance of osmotic agents in both prescription and over-the-counter markets continues to expand their presence in the constipation treatment drug market.

Prosecretory Agents:

Prosecretory agents represent a newer class of medications aimed at treating constipation by enhancing intestinal fluid secretion and improving motility. Agents like lubiprostone and linaclotide are effective in managing chronic idiopathic constipation and opioid-induced constipation. These drugs work by activating specific ion channels in the intestinal lining, promoting more effective bowel movements. The market for prosecretory agents is experiencing robust growth due to increased awareness among healthcare professionals about their benefits, particularly in patients who do not respond well to traditional laxatives. Their targeted action and improved patient outcomes are significant factors contributing to the rising adoption of this product type.

By Application

Chronic Idiopathic Constipation:

Chronic idiopathic constipation (CIC) refers to a common gastrointestinal disorder characterized by infrequent or difficult bowel movements without an identifiable medical cause. This condition affects millions of people worldwide and significantly impacts their quality of life. Treatment options for CIC often include a combination of lifestyle modifications, dietary changes, and pharmacological interventions, including laxatives and prosecretory agents. The rising awareness about CIC and the development of specialized treatments have led to increased market demand, as patients seek effective management strategies to alleviate discomfort and improve bowel regularity. Ongoing research into novel therapies continues to shape this application segment, providing hope for more effective management solutions.

Opioid-Induced Constipation:

Opioid-induced constipation (OIC) is a prevalent issue among patients receiving opioid therapy for chronic pain management. The potent effects of opioids on the gastrointestinal system often lead to significant discomfort and complications, necessitating effective treatment options. As the population of patients on opioid medications increases, the demand for targeted therapies to manage OIC is also on the rise. Medications specifically designed for OIC, including prosecretory agents and certain laxatives, are gaining traction due to their effectiveness in managing this side effect. Healthcare providers are increasingly aware of the importance of addressing OIC, which is propelling the growth of this application segment within the constipation treatment drug market.

Irritable Bowel Syndrome with Constipation:

Irritable bowel syndrome with constipation (IBS-C) is a complex gastrointestinal disorder characterized by abdominal pain, bloating, and altered bowel habits. Patients suffering from IBS-C often experience intermittent constipation, which complicates their management plans. The demand for effective treatments to alleviate the symptoms of IBS-C has led to the development of specific drugs targeting both constipation and associated symptoms. The availability of specialized medications, such as linaclotide and lubiprostone, designed specifically for IBS-C has helped in addressing the needs of this patient population. Increasing recognition of IBS-C in clinical settings is driving market growth as more patients seek effective treatments to manage their condition.

Others:

This category encompasses various other applications of constipation treatment drugs, including functional constipation and constipation related to lifestyle factors. Patients experiencing occasional constipation due to dietary habits, stress, or other transient factors may turn to over-the-counter laxatives and fiber supplements for relief. Additionally, emerging research into the effects of gut health on overall well-being is expanding the focus on constipation management in other gastrointestinal disorders. As awareness of the importance of digestive health increases, the demand for a diverse range of treatment options for various constipation-related conditions is also likely to grow, thereby contributing to the overall market expansion.

By Distribution Channel

Hospitals Pharmacies:

Hospital pharmacies play a crucial role in the distribution of constipation treatment drugs, particularly for patients requiring inpatient care or specialized treatments. These pharmacies are responsible for providing medications tailored to specific patient needs, including those with chronic constipation or those requiring opioid-induced constipation management. The integral role of hospital pharmacies in patient care ensures that individuals have access to effective treatments while under medical supervision. With healthcare institutions increasingly focusing on optimizing patient outcomes, the demand for constipation treatment drugs dispensed through hospital pharmacies is expected to witness steady growth in tandem with advancements in hospital care and patient management.

Retail Pharmacies:

Retail pharmacies serve as a primary distribution channel for constipation treatment drugs, providing easy access to over-the-counter laxatives and fiber supplements for consumers. The convenience of retail pharmacies allows patients to purchase medications without a prescription, encouraging self-medication for occasional constipation. The growing trend of health-conscious consumers seeking preventive measures for digestive health further enhances the role of retail pharmacies in the constipation treatment drug market. With many retail pharmacies expanding their product ranges to include specialized constipation therapies, this segment is expected to expand, driven by increased consumer demand and the convenience of access.

Online Pharmacies:

The rise of e-commerce has significantly transformed the way consumers purchase constipation treatment drugs, with online pharmacies gaining prominence as a convenient and often cost-effective option. These platforms provide easy access to both prescription and over-the-counter medications, allowing consumers to manage their health from the comfort of their homes. The COVID-19 pandemic has accelerated the shift toward online pharmacy services, as many individuals prefer remote consultations and home delivery options. As consumers become more comfortable with online shopping and the digital healthcare landscape continues to evolve, the online pharmacy segment is poised for substantial growth, contributing positively to the overall constipation treatment drug market.

By Ingredient Type

Polyethylene Glycol:

Polyethylene glycol (PEG) is a widely used ingredient in constipation treatment, particularly as an osmotic laxative. It works by drawing water into the intestines, resulting in softened stools and easier passage. PEG is considered to be effective and safe for both short-term and long-term use, making it a go-to choice for healthcare providers and patients alike. The wide availability of PEG-based formulations in various dosage forms, including powders and liquids, has contributed to its popularity. As awareness of PEG's benefits grows, its market share is expected to increase, particularly in the context of chronic constipation management.

Psyllium:

Psyllium, a natural soluble fiber derived from the seeds of the Plantago ovata plant, is a key ingredient in many fiber supplements used to treat constipation. It works by absorbing water in the intestines, thereby increasing stool bulk and promoting regular bowel movements. Psyllium is known for its safety and effectiveness, making it a preferred choice among consumers seeking natural remedies for constipation. The growing trend toward natural health products and dietary fibers is driving demand for psyllium-based formulations, positioning them as an essential component of the constipation treatment drug market.

Bisacodyl:

Bisacodyl is a widely recognized stimulant laxative used for the short-term relief of constipation. It works by stimulating the muscles of the intestines, promoting bowel movement. Bisacodyl is available in various forms, including tablets and suppositories, making it accessible for consumers seeking immediate relief. Its efficacy and quick action have made bisacodyl a commonly recommended option for occasional constipation. The market for bisacodyl is expected to grow in line with the increasing prevalence of constipation and the ongoing demand for effective, fast-acting treatments.

Lubiprostone:

Lubiprostone is a prosecretory agent that has gained popularity in the treatment of chronic idiopathic constipation and opioid-induced constipation. By activating chloride channels in the intestinal lining, lubiprostone enhances fluid secretion and promotes bowel movement. Its targeted action and proven efficacy have positioned it as a valuable option for patients who do not respond to traditional laxatives. The demand for lubiprostone is expected to rise as healthcare providers increasingly recognize the importance of addressing chronic constipation in their patients, especially those with opioid use.

Linaclotide:

Linaclotide is another prosecretory agent that is highly effective in treating chronic idiopathic constipation and irritable bowel syndrome with constipation. By stimulating the secretion of intestinal fluid and accelerating gastrointestinal transit, linaclotide provides relief from the discomfort associated with constipation. Its specific targeting of the underlying mechanisms of constipation sets it apart from traditional laxatives. The growing understanding of linaclotide's benefits and its increasing acceptance among healthcare providers are driving its market presence, contributing to the overall growth of the constipation treatment drug segment.

By Region

The constipation treatment drug market exhibits significant regional variation, influenced by factors such as healthcare infrastructure, patient demographics, and prevalence of gastrointestinal disorders. North America is currently the largest market for constipation treatment drugs, driven by high healthcare expenditure, widespread access to medications, and increasing awareness of gastrointestinal health. The region is expected to maintain its dominance throughout the forecast period, with a CAGR of approximately 5.5%. Europe follows closely, where a growing aging population and increased focus on preventive healthcare are contributing to market growth. The ongoing development of innovative treatment options in Europe is likely to further enhance its market position.

Asia Pacific is emerging as a rapidly growing region for constipation treatment drugs, attributed to the rising prevalence of constipation-related disorders and improving healthcare access. Countries such as Japan and China are experiencing significant growth in demand for both OTC and prescription medications for managing constipation. The rising awareness of gastrointestinal health and lifestyle changes in these countries are expected to support market expansion. Meanwhile, Latin America and the Middle East & Africa are also witnessing gradual growth, albeit at a slower pace compared to the other regions. Overall, the constipation treatment drug market is expected to continue its upward trajectory globally, driven by increasing consumer awareness and innovative treatment options.

Opportunities

The constipation treatment drug market presents several lucrative opportunities for stakeholders, particularly in terms of product innovation and market expansion. One of the key opportunities lies in the development of new formulations that offer targeted relief for specific patient populations, such as the elderly or those suffering from complex gastrointestinal disorders. As healthcare providers continue to seek effective solutions for managing chronic constipation, the introduction of novel drugs that combine multiple mechanisms of action holds promise for enhancing patient adherence and outcomes. Moreover, the growing trend of personalized medicine creates avenues for tailored treatment options that address the unique needs of individual patients, positioning companies favorably in an increasingly competitive market.

Furthermore, the rising demand for natural and organic products offers manufacturers an opportunity to formulate constipation treatment drugs that align with consumer preferences for health and wellness. As more people seek alternatives to synthetic medications, the incorporation of natural ingredients into formulations can serve to differentiate products in a crowded marketplace. Additionally, the expansion of online pharmacy services offers a strategic opportunity for companies to reach a broader audience, particularly younger consumers who prefer the convenience of e-commerce. By capitalizing on these emerging trends, stakeholders can position themselves for sustained growth within the constipation treatment drug market.

Threats

Despite the favorable growth prospects, the constipation treatment drug market faces several threats that could impede its progress. One significant challenge is the increasing competition from alternative therapies and natural remedies, which may lead to a decline in the market share of traditional medications. As consumers become more health-conscious and seek holistic solutions, the preference for non-pharmaceutical interventions such as dietary changes, probiotics, and herbal supplements is growing. This shift poses a threat to established pharmaceutical companies that rely on conventional drug sales for revenue. Additionally, stringent regulatory requirements and potential changes in legislation regarding over-the-counter medications could impact the approval and sale of constipation treatment products, leading to market uncertainty.

Another notable threat is the potential for side effects and safety concerns associated with long-term use of certain constipation treatment drugs. Patients may be hesitant to use stimulant laxatives due to the risk of dependency or diminished bowel function, which could hinder the overall market growth. Therefore, companies must invest in research and development to ensure the safety and efficacy of their products while also addressing consumer concerns. Failure to do so could result in a loss of consumer trust and market share, particularly as healthcare providers emphasize the importance of patient safety in treatment recommendations.

Competitor Outlook

• AbbVie Inc.
• Salix Pharmaceuticals
• Ironwood Pharmaceuticals, Inc.
• Johnson & Johnson
• Takeda Pharmaceutical Company Limited
• Procter & Gamble Co.
• Boehringer Ingelheim GmbH
• Novartis AG
• GSK (GlaxoSmithKline) Plc
• Sucampo Pharmaceuticals, Inc.
• Dr. Reddy's Laboratories Ltd.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Horizon Therapeutics plc
• Pfizer Inc.

The constipation treatment drug market is characterized by a diverse competitive landscape, with numerous key players actively participating in the sector. Companies such as AbbVie Inc., Ironwood Pharmaceuticals, and Salix Pharmaceuticals are at the forefront of innovation, focusing on the development of advanced therapies that address various forms of constipation. The market dynamics are driven by both established pharmaceutical giants and emerging biotech firms, all vying for market share through cutting-edge research and product offerings. The competitive landscape is marked by strategic collaborations, mergers, and acquisitions, as companies seek to fortify their positions and expand their portfolios in the growing constipation treatment space. Additionally, ongoing clinical trials and regulatory approvals play a crucial role in determining the market success of new entrants and existing players alike.

AbbVie Inc., a leading player in the biotechnology sector, has made significant strides in the constipation treatment market with its innovative drugs and robust R&D pipeline. The company's dedication to addressing unmet medical needs through the development of targeted therapies has positioned it as a frontrunner in the industry. Similarly, Ironwood Pharmaceuticals, recognized for its expertise in gastrointestinal treatments, continues to focus on advancing medication options for chronic constipation, particularly with its linaclotide product line. Salix Pharmaceuticals, a subsidiary of Bausch Health Companies, is another prominent player that specializes in gastrointestinal disorders, further solidifying its reputation in the constipation treatment market with a range of effective drug offerings. The concerted efforts of these companies, along with their emphasis on patient-centered care, are pivotal in shaping the future of constipation treatment therapies.

In addition to these major players, other pharmaceutical companies like Johnson & Johnson and Takeda Pharmaceutical Company Limited are also significant contributors to the constipation treatment drug market. Their extensive portfolios and established distribution networks enable them to reach a wide customer base, ensuring that effective constipation treatments are accessible to patients across various demographics. Moreover, ongoing research initiatives and investment in innovative drug formulations by these companies are critical to maintaining their competitive edge. As the market continues to evolve, the collaboration among industry players and the commitment to addressing patient needs will be vital in driving advancements in constipation management and enhancing treatment outcomes for individuals dealing with this common yet often overlooked condition.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 AbbVie Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Novartis AG
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Pfizer Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Sanofi S.A.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Johnson & Johnson
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Procter & Gamble Co.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Salix Pharmaceuticals
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Horizon Therapeutics plc
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Boehringer Ingelheim GmbH
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 GSK (GlaxoSmithKline) Plc
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Dr. Reddy's Laboratories Ltd.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Sucampo Pharmaceuticals, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Ironwood Pharmaceuticals, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Teva Pharmaceutical Industries Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Takeda Pharmaceutical Company Limited
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Constipation Treatment Drug Market, By Application
    • 6.1.1 Chronic Idiopathic Constipation
    • 6.1.2 Opioid-Induced Constipation
    • 6.1.3 Irritable Bowel Syndrome with Constipation
    • 6.1.4 Others
  • 6.2 Constipation Treatment Drug Market, By Product Type
    • 6.2.1 Laxatives
    • 6.2.2 Fiber Supplements
    • 6.2.3 Stimulants
    • 6.2.4 Osmotic Agents
    • 6.2.5 Prosecretory Agents
  • 6.3 Constipation Treatment Drug Market, By Ingredient Type
    • 6.3.1 Polyethylene glycol
    • 6.3.2 Psyllium
    • 6.3.3 Bisacodyl
    • 6.3.4 Lubiprostone
    • 6.3.5 Linaclotide
  • 6.4 Constipation Treatment Drug Market, By Distribution Channel
    • 6.4.1 Hospitals Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Constipation Treatment Drug Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Constipation Treatment Drug market is categorized based on

By Product Type

• Laxatives
• Fiber Supplements
• Stimulants
• Osmotic Agents
• Prosecretory Agents

By Application

• Chronic Idiopathic Constipation
• Opioid-Induced Constipation
• Irritable Bowel Syndrome with Constipation
• Others

By Distribution Channel

• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Polyethylene glycol
• Psyllium
• Bisacodyl
• Lubiprostone
• Linaclotide

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• AbbVie Inc.
• Salix Pharmaceuticals
• Ironwood Pharmaceuticals, Inc.
• Johnson & Johnson
• Takeda Pharmaceutical Company Limited
• Procter & Gamble Co.
• Boehringer Ingelheim GmbH
• Novartis AG
• GSK (GlaxoSmithKline) Plc
• Sucampo Pharmaceuticals, Inc.
• Dr. Reddy's Laboratories Ltd.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Horizon Therapeutics plc
• Pfizer Inc.